Although consensus statements support the preoperative treatment of borderline resectable pancreatic cancer, no prospective, quality-controlled, multicenter studies of this strategy have been conducted. Existing studies are retrospective and confounded by heterogeneity in patients studied, therapeutic algorithms used, and outcomes reported.
To determine the feasibility ...
JAMA Surg. Published online June 08, 2016. doi:10.1001/jamasurg.2016.1137